Renal protective effect of dpp-4 inhibitors in type 2 diabetes mellitus patients: a cohort study
Finally, the overwhelmingly positive preclinical literature is highly susceptible to publication bias, whereby neutral or negative findings are underreported
If anything, we should be shortening the interval between injections, not making it longer
The results reported a 6.0%, 6.8%, 9.1%, 9.7%, and 10.8% decrease in body weight for the groups receiving cagrilintide in doses of 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg, respectively [1]